Breaking News
September 19, 2018 - Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer
September 19, 2018 - Suicide: A public health crisis
September 19, 2018 - Stanford team will participate in NIH-funded study of tobacco policies | News Center
September 19, 2018 - Women with high levels of anti-Müllerian hormone more likely to develop breast cancer
September 19, 2018 - Effects of prematurity found to be more severe for the brains of males than females
September 19, 2018 - NIH funds CWRU to investigate new imaging approach for diagnosing peripheral arterial disease
September 19, 2018 - NUS researchers develop new device for quick and accurate screening of diseases
September 19, 2018 - Leading nutritionist explains about different types of iron in oral supplements
September 19, 2018 - New Crest Gum & Enamel Repair toothpaste may boost enamel repair and reverse gingivitis
September 19, 2018 - Analysis does not find any safety concerns of bivalent HPV vaccine
September 19, 2018 - Many Older Adults Transition to Long-Term Benzodiazepine Use
September 19, 2018 - Caregiving – resources – older adults: MedlinePlus Medical Encyclopedia
September 19, 2018 - Research shows that cystic fibrosis impacts growth in the womb
September 19, 2018 - Study shows how head, neck positioning affects concussion risk | News Center
September 19, 2018 - Antioxidant in green tea helps sneak therapeutic RNAs into cells
September 19, 2018 - Excess pregnancy weight gain affects cardiometabolic risk in offspring
September 19, 2018 - Penn researchers find common thread linking almost all TNR expansion diseases
September 19, 2018 - Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma
September 19, 2018 - Researchers use CRISPR screen to reveal new targets in squamous cell carcinomas
September 19, 2018 - UGR to coordinate the European H2020 project focused on Smart Personalized Nutrition
September 19, 2018 - Mumps Spread Quickly at Texas Cheerleading Meets: Study
September 19, 2018 - Addressing child stunting in Pakistan is critical
September 19, 2018 - Innovative system makes hospitals, clinics accessible for people with visual impairments
September 19, 2018 - CXCL14 protein is secreted by brown adipose tissue and has beneficial effects in metabolic diseases
September 19, 2018 - Air pollution increases risk of dementia
September 19, 2018 - Inequality issues persist even under new U.S. kidney transplant allocation system
September 19, 2018 - New study reveals mechanisms that lead to cognitive decline in Type 2 diabetes
September 19, 2018 - FDA launches new comprehensive effort to educate kids about dangers of e-cigarettes
September 19, 2018 - Study reveals mechanism underlying plants’ ability to signal defense
September 19, 2018 - Researchers harness Zika virus vaccine under development to target glioblastoma
September 19, 2018 - Novel deep learning drug discovery platform gets £1 million innovation boost
September 19, 2018 - Sensor array may detect de novo Parkinson’s disease in breath
September 19, 2018 - A roadmap for the future of electronic health records
September 19, 2018 - Surprising research showing peptide adaptability may pave way to develop immunotherapies
September 19, 2018 - Amyloid β protein makes comeback as therapeutic target for Alzheimer’s disease
September 19, 2018 - Alcon expands its global support of eye care professionals through Alcon Experience Academy
September 19, 2018 - Study gives new insights into how cells leverage GPCRs to control inflammation
September 19, 2018 - Automatic relevance detection in ophthalmic surgery videos
September 19, 2018 - UNIST to accelerate discovery, development of new medicines for incurable diseases
September 19, 2018 - Novel clinical trial to examine cannabis as potential treatment for essential tremor
September 19, 2018 - Salsa dancers have lower injury rates than Spanish, aerobic or Zumba dancers
September 19, 2018 - AmpliPhi receives positive feedback from FDA for its AB-PA01 product targeting P.aeruginosa infections
September 19, 2018 - Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial
September 19, 2018 - Can work stress contribute to Parkinson’s disease risk?
September 19, 2018 - Global Climate Action Summit: A focus on kids and climate
September 19, 2018 - Vitamin D may reduce breast cancer mortality in women with lower BMI
September 19, 2018 - Targeted Lung Denervation procedure significantly reduces COPD problems
September 19, 2018 - FDA-approved ‘safe’ daily BPA exposure may contribute to insulin resistance
September 19, 2018 - Research finds physical connection between the brain’s fluid reservoirs and meningeal lymphatics
September 19, 2018 - UCalgary study could help physicians make better treatment decisions for stroke
September 19, 2018 - Biomedical review finds failure rates in some surgical mesh treatments to be unacceptably high
September 19, 2018 - Researchers develop more accurate measure of body fat
September 19, 2018 - Doctors and students rally to support gun violence research, education
September 19, 2018 - LEO Pharma and MorphoSys announce expansion of strategic alliance to develop peptide-derived drugs
September 19, 2018 - Seniors in pain hop aboard the canna-bus
September 19, 2018 - New compound could prevent malaria parasites from maturing inside mosquito
September 19, 2018 - Scientists find alterations in blood flow in response to body position change
September 19, 2018 - UNC Health Care extends free access to virtual care service in the aftermath of Hurricane Florence
September 19, 2018 - Opioid Refills Rare After Rhinoplasty
September 19, 2018 - Corn, obesity, and navigating healthy eating choices as a parent
September 19, 2018 - Journal editor aims to prompt thoughtful review of ethics in precision health
September 19, 2018 - Researchers identify key step in how plant cells respond to pathogens
September 18, 2018 - Researchers analyze how exposure to silver nanoparticles affects zebrafish
September 18, 2018 - Study shows air pollution may be bad for the fetus
September 18, 2018 - Coffee May Have Another Perk for Kidney Patients
September 18, 2018 - Tongue-in-cheek Nobels honor nutritional analysis of cannibalism, roller-coaster kidney stones treatment
September 18, 2018 - Progress, priorities, challenges are focus of State of Stanford Medicine | News Center
September 18, 2018 - Established Alzheimer’s Risk Gene Has a New Role
September 18, 2018 - Hospitalization after antibiotic initiation found to be higher for people with Alzheimer’s disease
September 18, 2018 - Many children with special healthcare needs do not have access to ‘PCMH-concordant’ care
September 18, 2018 - Investigational nasal influenza vaccine tested in children and teens
September 18, 2018 - Lymphatic vessels surrounding the brain play crucial role in multiple sclerosis, research suggests
September 18, 2018 - New fiber laser-based ultrasound sensor may have potential applications in medical diagnostics
September 18, 2018 - Protect your heart and health during ‘dog days’ of summer
September 18, 2018 - Faculty receive awards for promise in biomedical research, clinical care | News Center
September 18, 2018 - Digital games for CVD-related self-management improve exercise capacity and energy expenditure
September 18, 2018 - Aluminum inclusions help enhance adsorption of chemo drugs onto active carbon delivery capsule
September 18, 2018 - Adding PET scans to CT imaging can change treatment for women with cervical cancer
September 18, 2018 - UCSF awarded $20 million grant to study impacts of new, emerging tobacco products
September 18, 2018 - Human brains may be wired to prefer lying on the couch, suggests research
UC San Diego launches new bacteriophage therapy center

UC San Diego launches new bacteriophage therapy center

image_pdfDownload PDFimage_print

With microbial resistance to antibiotics growing into a major global health crisis, researchers at University of California San Diego School of Medicine, in collaboration with national research institutions and private industry, are leveraging hard-won expertise to exploit a natural viral enemy of pathogenic bacteria, creating North America’s first Center for Innovative Phage Applications and Therapeutics (IPATH).

Bacteriophages, or phages, are viruses that specifically target and consume bacteria. They are ubiquitous, found wherever bacteria exist and were once considered a promising therapeutic tool. The advent of modern antibiotics in the 1930s redirected research interests, but with 10 million people estimated to die from “superbug” infections by 2050, they are getting a second look.

In 2016, UC San Diego School of Medicine physicians and scientists conducted a dramatic, last-ditch effort to save the life of Tom Patterson, PhD, then a 69-year-old professor in the Department of Psychiatry at UC San Diego School of Medicine who had become systemically infected by a multidrug-resistant bacterium during a vacation in the Middle East.

Comatose and dying, a team that included experts from UC San Diego, the U.S. Navy, Texas A&M University, San Diego State University and private industry developed experimental cocktails of bacteriophages to treat Patterson. The approach worked; Patterson awoke within days and fully recovered. He was the first U.S. patient with a systemic multidrug-resistant bacterial infection to be successfully treated intravenously with bacteriophages. In the two years since, physicians at UC San Diego Health have treated five other patients with phages for bacterial infections under emergency investigational new drug approval from the Food and Drug Administration (FDA).

“All of the patients tolerated phage therapy well without adverse effects,” said Saima Aslam, MD, associate professor of medicine and medical director of the solid organ transplant infectious diseases service at UC San Diego Health. “Phage combinations were given by direct instillation into the infected site, intravenously and/or by inhaled routes. This led to resolution of infection in three cases. In two others, it helped ameliorate the infection. In one case, treatment came too late in the course of infection and the patient was transitioned to hospice.”

Encouraged by the broadly positive results observed in these first patients, UC San Diego Chancellor Pradeep Khosla has announced a three-year, $1.2 million grant to help launch the center.

“The story of how phages saved Tom’s life and have helped others, the tremendous depth of scientific knowledge and medical practice, combined with intuition, innovation and just sheer guts, is what UC San Diego is all about,” said Khosla. “IPATH captures many of our most cherished ambitions: a robust, interdisciplinary research that advances science, but also delivers tangible benefits to patients and society. Phage therapy has the potential to save millions of lives.”

Steffanie Strathdee, PhD, associate dean of global health sciences and Harold Simon Professor in the Department of Medicine, and Robert Schooley, MD, professor of medicine and an infectious disease expert at UC San Diego School of Medicine, will be co-directors of IPATH. It was Strathdee, who is married to Patterson, who collaborated with Schooley and others to seek an emergency compassionate-use exemption to experimentally treat her husband with phages after all standard antibiotic treatments failed.

“IPATH builds upon what we’ve learned and will apply rigorous principles that span from bench to bedside to better understand the potential role for phage therapeutics in the treatment of patients with infections that cannot successfully be treated with currently available antibiotics,” said Strathdee.

“It taps into and enhances a wide range of existing clinical and translational research programs -; there are few places in the world with similar resources to treat multidrug-resistant bacterial infections -; and fosters emerging collaborations with the U.S. Navy Medical Research Center, industry partners and the strengths of the UC San Diego Health system.”

The center will begin with multiple key personnel:

Strathdee
Schooley
Aslam
Davey Smith, MD, chief, Division of Infectious Diseases and Global Public Health
Constance Benson, MD, professor of medicine
Michelle Ritter, MD, assistant professor of medicine
Randy Taplitz, MD, professor of medicine and Clinical Director of the Division of Infectious Diseases
Sharon Reed, MD, professor of pathology and medicine
David Pride, MD, PhD, assistant professor of pathology and medicine
Darcy Wooten, MD, assistant professor of medicine
Jenifer Dan, MD, PhD, senior fellow, division of infectious diseases
Doug Conrad, MD, professor of medicine
Rob Knight, PhD, director, Center for Microbiome Innovation; professor of pediatrics, computer science and engineering
Bernd Schnabl, PhD, associate professor of gastroenterology
Victor Nizet, MD, professor, Skaggs School of Pharmacy and Pharmaceutical Sciences and Department of Pediatrics
Pieter Dorrestein, PhD, professor, Skaggs School of Pharmacy and Pharmaceutical Sciences and department of Pediatrics and Pharmacology

Strathdee and Schooley said IPATH will use existing resources at UC San Diego Antiviral Research Center to build the infrastructure needed to validate phage therapy for treating multidrug-resistant bacterial infections in clinical settings.

It will also partner with other like-minded institutions, including the Center for Phage Technology (CPT) at Texas A&M University, San Diego State University and two biotechnology companies specializing in the development of therapeutic bacteriophages: Ampliphi Biosciences, based in San Diego, and Adaptive Phage Therapeutics, Inc. or APT, based in Maryland.

“The CPT has been developing phages as agents for combating bacterial infections in plants, animals and humans since 2010, and promoting best practices for the ethical and sustainable use of this technology,” said Ryland F. Young III, CPT director and Regents Professor at Texas A&M. “The CPT fully supports the establishment of IPATH at UC San Diego, and based on our past collaboration that resulted in successful application of phage therapeutics, we look forward to fruitful interactions in the future.”

Schooley said a primary goal of IPATH is to conduct rigorous clinical trials of phage therapies, thus advancing their potential to practical application: “The clinical research will be integrated with leading-edge translational and basic research that will provide critical insights into the mechanisms by which phage selectively kill their bacterial targets, and that will accelerate the development of more advanced clinical research that we hope will lead the FDA to make phage therapeutics more widely available.

“That requires a lot of things: clinical trial infrastructure and design expertise, microbiome expertise, a patient population needing novel interventions like phage therapy who wish to join us in this journey. Although all of these elements are here, we plan to work with a wide range of partners around the world to advance phage therapeutics from anecdote to a globally available tool to combat the rising tide of multidrug resistant infections.”

Initial research will focus on patients with multidrug-resistant chronic infections associated with cystic fibrosis, organ transplantation and implantable hardware, such as pacemakers or joint replacements.

“The launch of IPATH is a momentous and gratifying step,” said Hubert Mazure, the great-grandson of Félix d’Herelle, the French-Canadian microbiologist who discovered bacteriophages in 1917 at the Pasteur Institute and was the first to experiment with them in treating human diseases caused by pathogenic bacteria. “This is the kind of effort needed to truly and fully explore the healing potential of bacteriophages in the modern era.”

Source:

http://ucsdnews.ucsd.edu/pressrelease/turning_a_phage

Tagged with:

About author

Related Articles